**MINUTES**

**CPIC CONFERENCE CALL**

DATE: May 4, 2023

| TOPIC | DISCUSSION/ACTION | FOLLOW-UP |
| --- | --- | --- |
| Housekeeping announcements | Attendance will be taken by poll after each conference call. Members will receive an email with a poll link after each call. Please enter your first and last name and check the box indicating you were in attendance. No action required if you were unable to make the conference call. | Kelly will send the poll link. |
| Reviewers needed for NCBI Medical Genetics Summaries | The team at NCBI needs reviewers for the Medical Genetics Summaries PGx chapters. This does not equate to an obligation or commitment to review any specific chapter, just a willingness to be contacted as a potential reviewer. Chapters encompass a range of PGx topics; oncology medications, drugs covered on the “All of Us” PGx results, and rare disease medications are some of the topics they have been researching lately. Turnaround time for these reviews is flexible but aim for 2-3 weeks. | If you are interested, please contact NCBI at [mgs@ncbi.nlm.nih.gov](mailto:mgs@ncbi.nlm.nih.gov) . |
| CPIC guidelines in progress | * SSRI/SNRI guideline update – published ([cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants](https://cpicpgx.org/guidelines/cpic-guideline-for-ssri-and-snri-antidepressants/)) * *CYP3A5*/tacrolimus update – in evidence review * *CYP2D6*/antipsychotics – in evidence review; other genes being considered * Beta blockers – finalizing manuscript and will be sent out for CPIC member review soon * *CYP2B6*/methadone – drafting manuscript * *UGT1A1*/irinotecan – preliminary evidence review being conducted by the St. Jude Children’s Research Hospital Clinical Pharmacogenomics resident * *NAT2/*hydralazine – authorship plan underway | Email Kelly ([kelly.caudle@stjude.org](mailto:kelly.caudle@stjude.org)) if you are interested in serving as an author on the *NAT2*/hydralazine guideline |
| Beta-blocker guideline | Currently have a draft of the beta-blocker guideline (genes evaluated: *CYP2D6*, *ADRB1*, *ADRB2*, *GRK4*, *GRK5*). Julio Duarte, PharmD, PhD, presented the background for these gene/drug associations and associated clinical recommendations from the CPIC guideline author group. |  |
| From pilot to expansion: Feasibility of pharmacogenetics beyond large academic hospitals – Nihal El Rouby | Nihal El Rouby, PharmD, PhD discussed the clinical implementation of pharmacogenomics at St. Elizabeth Hospital, a community-based hospital. Slides included with the minutes. |  |